U.S. FDA Approves Gilead's Once-Daily HIV Pill Bixlenvo
The U.S. Food and Drug Administration has approved Gilead Sciences' (GILD) once-daily oral antiviral medication, Bixlenvo, for the treatment of HIV in adults. This marks a significant advancement as it is now recognized as the smallest single-tablet regimen available for managing the condition. Bixlenvo combines bictegravir, an integrase inhibitor developed by Gilead, with two other antiretroviral drugs—emtricitabine and tenofovir alafenamide. The approval highlights a shift toward more convenient treatment options in HIV care, potentially improving patient adherence. The once-daily dosing is expected to enhance the quality of life for patients while reducing pill burden compared to existing regimens.
Tickers: $GILD